Professional Documents
Culture Documents
High sensitiveTroponin I
Chest pain is among the reasons to visit an emergency department (ED),
accounting for about 5% of all ED visits (2)
Expected prevalence of acute myocardial infarction (MI) in chest pain patients in the ED (3)
5-10% 15-20%
STEMI NSTEMI Deliver high performance
INTENDED USE:
Optimize the management of ACS Aid in the diagnosis of myocardial infarction.
19 CV
●
AT 2 HOURS T2h
Re-test VIDAS HsTnI
T0 AND T2h ∆ T2h - T0
< 6 ng/L Others ≥ 10 ng/L
● Algorithm based on admission values and absolute changes within the first 2 hours.
DIAGNOSIS RISK STRATIFICATION ● Delivers a diagnosis - safe rule-out and accurate rule-in - of acute MI (NSTEMI) in the vast
majority (70%) of suspected chest pain patients.
● Mandatory tool, in addition to clinical ● Additional tool in risk stratification ● Shortens the time needed to triage chest pain patients in the ED (will obviate the need for
assessment and ECG, to make a definitive to guide therapeutic decision making. prolonged monitoring with frequent serial blood sampling).
diagnosis of acute MI.
● Serial measurement to differentiate acute
ST – segment elevation myocardial infarction
from chronic cardiac myocyte damage. Non – ST – segment elevation myocardial infarction
Acute Coronary Syndrome ∆: Difference in cTn concentration NPV: Negative Predictive Value PPV: Predictive Positive Value
AVAILABLE ON VIDAS®
INSTRUMENTS:
VIDAS®, MINI VIDAS®
AND VIDAS® 3
belonging to bioMérieux, or one of its subsidiaries or one of its companies. Any other trademark is the property of its respective owner. VIDAS apparatus is a used, pending and/or registered designs belonging to bioMérieux or one of
VIDAS® offers your lab simplicity and productivity. It will enhance your workflow, allowing you to
01/18/ 9312992/008/GB/D / Document and/or pictures not legally binding. Modifications by bioMérieux can be made without prior notice / BIOMÉRIEUX, the blue logo and VIDAS are used, pending and/or registered trademarks
REFERENCES
1. Lozano R, et al. Lancet.2012;380:2095-128.
2. Bandstein N, et al. J Am Coll Cardiol. 2014;63:2569-78.
3. Mueller C, et al. Eur Heart J. 2015 Aug 29. pii: ehv409.
4. Roffi M, et al. Eur Heart J. 2015 Aug 29. pii: ehv320.
5. Lindahl B, et al. Heart. 2017;103:125-131
bioMérieux S.A. • 69280 Marcy l’Etoile • France • Tel.: + 33 (0)4 78 87 20 00 • Fax: +33 (0)4 78 87 20 90
www.biomerieux.com • www.biomerieux-diagnostics.com